Replimune Group Q3 EPS Estimate Reduced by HC Wainwright

Replimune Group, Inc. (NASDAQ:REPL) – Investment analysts at HC Wainwright cut their Q3 2026 earnings estimates for shares of Replimune Group in a research report issued on Thursday, November 6th. HC Wainwright analyst R. Burns now anticipates that the company will post earnings of ($0.83) per share for the quarter, down from their prior forecast of ($0.82). HC Wainwright has a “Buy” rating and a $12.00 price objective on the stock. The consensus estimate for Replimune Group’s current full-year earnings is ($2.97) per share. HC Wainwright also issued estimates for Replimune Group’s Q4 2026 earnings at ($0.78) EPS, FY2026 earnings at ($3.46) EPS, Q1 2027 earnings at ($0.65) EPS, Q4 2027 earnings at ($0.32) EPS and FY2027 earnings at ($1.92) EPS.

Other analysts have also issued research reports about the stock. Weiss Ratings restated a “sell (e+)” rating on shares of Replimune Group in a research note on Wednesday. Wedbush raised shares of Replimune Group from a “neutral” rating to an “outperform” rating and boosted their target price for the stock from $4.00 to $18.00 in a research report on Monday, October 20th. Jefferies Financial Group reduced their price target on shares of Replimune Group from $31.00 to $6.00 and set a “buy” rating on the stock in a research report on Tuesday, July 22nd. Piper Sandler upgraded Replimune Group from a “neutral” rating to an “overweight” rating and set a $13.00 price target for the company in a research note on Monday, October 20th. Finally, JPMorgan Chase & Co. upgraded Replimune Group from an “underweight” rating to a “neutral” rating and set a $11.00 price objective on the stock in a research note on Monday, October 20th. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, two have issued a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, Replimune Group presently has an average rating of “Moderate Buy” and an average price target of $9.75.

Replimune Group Price Performance

REPL stock opened at $8.31 on Monday. The stock’s 50 day moving average is $6.14 and its two-hundred day moving average is $7.41. Replimune Group has a 52-week low of $2.68 and a 52-week high of $17.00. The company has a market capitalization of $651.84 million, a PE ratio of -2.40 and a beta of 0.79. The company has a quick ratio of 6.94, a current ratio of 6.94 and a debt-to-equity ratio of 0.21.

Replimune Group (NASDAQ:REPL) last announced its earnings results on Thursday, November 6th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.87) by ($0.03).

Institutional Trading of Replimune Group

Hedge funds have recently made changes to their positions in the stock. Vanguard Group Inc. boosted its position in Replimune Group by 6.6% during the 1st quarter. Vanguard Group Inc. now owns 3,833,033 shares of the company’s stock valued at $37,372,000 after purchasing an additional 237,185 shares during the period. Readystate Asset Management LP boosted its holdings in shares of Replimune Group by 1,296.2% during the third quarter. Readystate Asset Management LP now owns 2,621,012 shares of the company’s stock valued at $10,982,000 after acquiring an additional 2,433,292 shares during the period. Millennium Management LLC grew its position in shares of Replimune Group by 2.8% during the first quarter. Millennium Management LLC now owns 1,223,236 shares of the company’s stock worth $11,927,000 after acquiring an additional 33,574 shares during the last quarter. MPM Bioimpact LLC increased its holdings in shares of Replimune Group by 3.9% in the 1st quarter. MPM Bioimpact LLC now owns 987,036 shares of the company’s stock worth $9,624,000 after acquiring an additional 37,036 shares during the period. Finally, Parkman Healthcare Partners LLC lifted its position in Replimune Group by 9.3% in the 1st quarter. Parkman Healthcare Partners LLC now owns 950,399 shares of the company’s stock valued at $9,266,000 after purchasing an additional 80,640 shares during the last quarter. Institutional investors own 92.53% of the company’s stock.

Insider Transactions at Replimune Group

In other Replimune Group news, CFO Emily Luisa Hill sold 9,154 shares of the firm’s stock in a transaction dated Friday, August 15th. The shares were sold at an average price of $5.37, for a total value of $49,156.98. Following the transaction, the chief financial officer owned 134,368 shares of the company’s stock, valued at $721,556.16. This trade represents a 6.38% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. 5.20% of the stock is owned by corporate insiders.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.